오소바이오로직스 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of orthobiologics Market

The global orthobiologics market is witnessing substantial growth driven by the rising prevalence of bone and musculoskeletal disorders, increasing orthopedic injuries, and the adoption of regenerative medicine. The market was valued at USD 9.7 billion in 2025, projected to reach USD 10.22 billion in 2026, and is expected to grow to USD 15.06 billion by 2034, exhibiting a CAGR of 5.00% during the forecast period. North America dominated the market in 2025, capturing a 47.69% share, owing to rapid adoption of biologics for bone-related injuries, the large patient pool, and a high volume of orthopedic surgeries.

Orthobiologics are products derived from naturally occurring substances in the body, used to enhance the healing of bones, ligaments, tendons, and muscles. They are widely used in orthopedic procedures to repair bone defects and promote tissue regeneration. The increasing use of stem cell-based allografts and other biologics in orthopedic treatments is expected to further fuel market growth.

During the COVID-19 pandemic, the market experienced a temporary decline due to reduced patient visits, reallocation of healthcare resources, and supply chain disruptions. In 2020, the market revenue declined by 10.6%, but recovery began in 2021 with rising patient volumes, vaccination coverage, and resumption of orthopedic surgeries. By 2022, the market returned to pre-pandemic levels, as highlighted by Johnson & Johnson Services, Inc., which reported net sales of USD 94,943 million, including significant contributions from orthopedic products.

Market Trends

A major trend driving the market is the increased use of viscosupplements to delay total knee replacement procedures. Viscosupplements restore the rheological properties of synovial fluid, reduce pain, improve joint function, and promote cartilage regeneration. Studies indicate that treatment with hyaluronic acid injections can delay total knee replacement surgery by over one year, contributing to the growing adoption of viscosupplements.

Market Drivers

The rising incidence of orthopedic injuries, bone fractures, osteoporosis, and sports-related traumas is fueling the demand for orthobiologic products. In the U.S. alone, over 6.8 million patients seek treatment for orthopedic injuries annually. The increasing prevalence of hip and spinal fractures, along with road accidents, is also supporting market expansion.

Another driver is the launch of new orthobiologics products, including allografts, bone growth factors, and synthetic bone substitutes. For example, Royal Biologics launched MAGNUS, a DMSO-free viable cellular bone allograft in 2020, while Biocomposites received CE approval for antibiotic-eluting bone void fillers. Continuous product innovation ensures the availability of advanced solutions for bone repair, enhancing market growth.

Market Restraints

The market faces constraints due to clinical limitations of certain orthobiologics and issues associated with bone morphogenetic proteins (BMPs). Medtronic's INFUSE, a widely used BMP, has been associated with serious side effects such as infections, urinary problems, bone/nerve injury, and potential cancer risk. Adverse tissue reactions, incomplete bone formation, and soft tissue infections with other orthobiologics also limit widespread adoption.

Market Segmentation

By Product Type

• Viscosupplements held a dominant share of 31.51% in 2026, driven by increasing prevalence of knee osteoarthritis among the aging population.
• Synthetic bone substitutes are expected to record the highest CAGR due to adoption in developed regions and focus on new product launches.
• Demineralized Bone Matrix (DBM) and cellular allografts also contribute significantly due to enhanced osteoinductive properties and minimally invasive applications.

By Application

• Spinal fusion led the market with 31.12% share in 2026, fueled by increasing spinal surgeries globally and approvals for new orthobiologics.
• Reconstructive & fracture surgeries accounted for the second-largest market share due to rising prevalence of fractures and osteoporosis.

By End-User

• Hospitals & Ambulatory Surgery Centers (ASCs) dominated with 61.35% market share in 2026, supported by high patient volumes and orthopedic procedures.
• Specialty clinics are expected to grow significantly due to increasing need for specialized care in orthopedic treatments.

Regional Insights

• North America: Valued at USD 4.63 billion in 2025, projected to reach USD 4.51 billion in 2026, driven by large patient base and advanced healthcare infrastructure.
• Europe: Second-largest market, with Germany reaching USD 0.75 billion and the UK USD 0.53 billion by 2026, supported by R&D investments and positive clinical trials.
• Asia Pacific: Highest CAGR expected due to under-penetration of orthobiologics, large patient pool, and rising bone disease prevalence. Japan, China, and India are projected to reach USD 0.72, 0.55, and 0.3 billion, respectively, by 2026.
• Latin America & Middle East & Africa: Moderate growth driven by increasing awareness, adoption of novel biologics, and improving healthcare infrastructure.

Competitive Landscape

Key players include Medtronic (Ireland), Zimmer Biomet (U.S.), DePuy Synthes (U.S.), Stryker (U.S.), Anika Therapeutics, Inc. (U.S.), SeaSpine (U.S.), Bioventus (U.S.), RTI Surgical (U.S.), MTF Biologics (U.S.), Arthrex, Inc. (U.S.), and Smith & Nephew (U.K.). Recent developments include:

• October 2023 - Orthofix Medical launched OsteoCove, a bioactive synthetic graft.
• June 2023 - Anika Therapeutics received FDA 510(k) clearance for Tactoset Injectable Bone Substitute.
• March 2023 - LifeNet Health launched ViviGen MIS, a viable bone matrix for MIS spine procedures.

Conclusion

The orthobiologics market is set to grow from USD 9.7 billion in 2025 to USD 15.06 billion by 2034, driven by the increasing prevalence of orthopedic injuries, the adoption of viscosupplements, spinal fusion procedures, and the launch of innovative biologic products. While clinical limitations of certain BMPs and bone graft substitutes may restrain growth, the rising demand for advanced, minimally invasive orthopedic treatments ensures continued market expansion.

Segmentation

By Product Type

• Viscosupplements
• Bone Growth Factors
• Demineralized Bone Matrix (DBM)
• Synthetic Bone Substitutes
• Cellular Allograft
• Others

By Application

• Spinal Fusion
• Maxillofacial & Dental
• Soft Tissue Repair
• Reconstructive & Fracture Surgery
• Others

By End-user

• Hospitals & ASCs
• Specialty Clinics
• Others

By Geography

• North America (By Product Type, By Application, By End-user, and By Country)
  • U.S. (By Application)
  • Canada (By Application)
• Europe (By Product Type, By Application, By End-user, and By Country/Sub-region)
  • Germany (By Application)
  • U.K. (By Application)
  • France (By Application)
  • Italy (By Application)
  • Scandinavia (By Application)
  • Rest of Europe (By Application)
• Asia Pacific (By Product Type, By Application, By End-user, and By Country/Sub-region)
  • China (By Application)
  • India (By Application)
  • Japan (By Application)
  • Australia (By Application)
  • Southeast Asia (By Application)
  • Rest of Asia Pacific (By Application)
• Latin America (By Product Type, By Application, By End-user, and By Country/Sub-region)
  • Brazil (By Application)
  • Mexico (By Application)
  • Rest of Latin America (By Application)
• Middle East & Africa (By Product Type, By Application, By End-user, and By Country/Sub-region)
  • South Africa (By Application)
  • GCC (By Application)
  • Rest of Middle East & Africa (By Application)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Epidemiology of Clinical Indications
• 4.2. Regulatory Scenario for Key Countries
• 4.3. New Product Launches
• 4.4. Key Industry Developments (Mergers, Acquisitions, and Partnership)
• 4.5. Impact of COVID-19 on the Market

5. Global Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Viscosupplements
  • 5.1.2. Bone Growth Factors
  • 5.1.3. Demineralized Bone Matrix (DBM)
  • 5.1.4. Synthetic Bone Substitutes
  • 5.1.5. Cellular Allograft
  • 5.1.6. Allografts
  • 5.1.7. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Spinal Fusion
  • 5.2.2. Maxillofacial & Dental
  • 5.2.3. Soft Tissue Repair
  • 5.2.4. Reconstructive & Fracture Surgery
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Hospitals & ASCs
  • 5.3.2. Specialty Clinics
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Viscosupplements
  • 6.1.2. Bone Growth Factors
  • 6.1.3. Demineralized Bone Matrix (DBM)
  • 6.1.4. Synthetic Bone Substitutes
  • 6.1.5. Cellular Allograft
  • 6.1.6. Allografts
  • 6.1.7. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Spinal Fusion
  • 6.2.2. Maxillofacial & Dental
  • 6.2.3. Soft Tissue Repair
  • 6.2.4. Reconstructive & Fracture Surgery
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Hospitals & ASCs
  • 6.3.2. Specialty Clinics
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Application
  • 6.4.2. Canada
    • 6.4.2.1. By Application

7. Europe Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Viscosupplements
  • 7.1.2. Bone Growth Factors
  • 7.1.3. Demineralized Bone Matrix (DBM)
  • 7.1.4. Synthetic Bone Substitutes
  • 7.1.5. Cellular Allograft
  • 7.1.6. Allografts
  • 7.1.7. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Spinal Fusion
  • 7.2.2. Maxillofacial & Dental
  • 7.2.3. Soft Tissue Repair
  • 7.2.4. Reconstructive & Fracture Surgery
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Hospitals & ASCs
  • 7.3.2. Specialty Clinics
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.4.1. Germany
    • 7.4.1.1. By Application
  • 7.4.2. U.K.
    • 7.4.2.1. By Application
  • 7.4.3. France
    • 7.4.3.1. By Application
  • 7.4.4. Italy
    • 7.4.4.1. By Application
  • 7.4.5. Spain
    • 7.4.5.1. By Application
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Application
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Application

8. Asia Pacific Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Viscosupplements
  • 8.1.2. Bone Growth Factors
  • 8.1.3. Demineralized Bone Matrix (DBM)
  • 8.1.4. Synthetic Bone Substitutes
  • 8.1.5. Cellular Allograft
  • 8.1.6. Allografts
  • 8.1.7. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Spinal Fusion
  • 8.2.2. Maxillofacial & Dental
  • 8.2.3. Soft Tissue Repair
  • 8.2.4. Reconstructive & Fracture Surgery
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Hospitals & ASCs
  • 8.3.2. Specialty Clinics
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.4.1. China
    • 8.4.1.1. By Application
  • 8.4.2. India
    • 8.4.2.1. By Application
  • 8.4.3. Japan
    • 8.4.3.1. By Application
  • 8.4.4. Australia
    • 8.4.4.1. By Application
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Application
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Application

9. Latin America Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Viscosupplements
  • 9.1.2. Bone Growth Factors
  • 9.1.3. Demineralized Bone Matrix (DBM)
  • 9.1.4. Synthetic Bone Substitutes
  • 9.1.5. Cellular Allograft
  • 9.1.6. Allografts
  • 9.1.7. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Spinal Fusion
  • 9.2.2. Maxillofacial & Dental
  • 9.2.3. Soft Tissue Repair
  • 9.2.4. Reconstructive & Fracture Surgery
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Hospitals & ASCs
  • 9.3.2. Specialty Clinics
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.4.1. Brazil
    • 9.4.1.1. By Application
  • 9.4.2. Mexico
    • 9.4.2.1. By Application
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Application

10. Middle East & Africa Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Viscosupplements
  • 10.1.2. Bone Growth Factors
  • 10.1.3. Demineralized Bone Matrix (DBM)
  • 10.1.4. Synthetic Bone Substitutes
  • 10.1.5. Cellular Allograft
  • 10.1.6. Allografts
  • 10.1.7. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Spinal Fusion
  • 10.2.2. Maxillofacial & Dental
  • 10.2.3. Soft Tissue Repair
  • 10.2.4. Reconstructive & Fracture Surgery
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By End-user
  • 10.3.1. Hospitals & ASCs
  • 10.3.2. Specialty Clinics
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.4.1. South Africa
    • 10.4.1.1. By Application
  • 10.4.2. GCC
    • 10.4.2.1. By Application
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Application

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Medtronic
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Zimmer Biomet
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. DePuy Synthes (Johnson & Johnson Services, Inc.)
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Stryker
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Anika Therapeutics, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. SeaSpine
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Bioventus
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. RTI Surgical
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. MTF Biologics
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Arthrex, Inc.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. Smith & Nephew
    • 11.2.11.1. Overview
    • 11.2.11.2. Products
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)